Uncer the Paperviols Reduction Act or Issid, no persons are required

Applicat

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		09771382		
Filing Date			2001-01-25		
	First Named Inventor Ian R		chard Anselm Peak et al.		
	Art Unit		1645		
Examiner Name Vanes		Vane	isa L. Ford		
	Attorney Docket Number		8795-24U1		

					U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue C	Date	Name of Pat of cited Docu	entee or Applicant ument	Releva	Columns,Lines whent Passages or Res Appear	
	1									
If you wisl	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Cite Publication Number Kind Publication Name of Patentee of cited Document			Releva	Columns,Lines when the Passages or Research						
	1									
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information	please click the Ad	d button		
				FOREIG	3N PAT	TENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Li where Relevant Passages or Relev Figures Appear	TE
	1	0 273 116	EP		A2	2007-04-23	MAX-PLANCK- GESELLSCHAFT ZUR FORDERUNG DER			
	2	90/06696 WO A2 1990-06-28 PRAXIS BIOLOGII INC.		CS,						
	3	97/46582	wo		A1	1997-12-11	PEPTIDE THERAPEUTICS LIMITED			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09771382		
Filing Date		2001-01-25		
First Named Inventor	Ian R	ichard Anselm Peak et al.		
Art Unit		1645		
Examiner Name	Vane	ssa L. Ford		
Attaces on Desirat North	or	9705 24114		

	4	01/04316	wo	A2	2001-01-18	CHIRON S.P.A.				
	5	00/61165	wo	A1	2000-10-19	SMITHKLINE BEECHAM CORPORATION				
	6	00/66741	wo	A2	2000-11-09	CHIRON S.P.A.				
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add buttor	Add			
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove			
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* No (blook, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city andice country where published.									
	1	ANNIKA PETTERSSON et al., "Sequence variability of the meningococcal ladoferm-binding protein LbpB," Gene 231:105-110 (1999)								
	2	JOHN E. HECKELS et al., "Vaccination against gonorrhoea, the potential protective effect of immunization with a synthetic peptide containing a conserved epitope of genococcal outer membrane protein IB," Vaccine 8,225-230 (June [1990])								
	MARIAGRAZIA FIZZA et al., (XP-000914964) "Identification of Vaccine Candidates Against Serogroup B 3 Meringococcus by Whole-Genome Sequencing," Science 297 1516-1520 (March 10, 2000) with XP002312283 - EBI accession no UMPROT 054115- Distables accession no UMPROT 054115- Distables accession no UMPROT 054116- Distables accession no UMP									
	4 IAN R. A. PEAK et al., "Gentification and characterisation of a novel conserved outer membrane protein from Nesseria meningibids," FEMS immunology and Medical Microbiology 28:329-334 (2000)									
	5	J PARKHILL et al., (XP-000918875) "Complete DNA sequence of a serogroup A strain of Neisseria meningflids Z2491." Nature 404-502-505 (March 30, 2000)								
	6	HERVE TETTELIN et al MC58," Science 287: 18				quence of Neisseria mening	gibdis Serogroup B Strain			
If you wis	h to a	i dd additional non-paten	t literature docu	ment ci	tation informat	ion please click the Add I	outton Add	_		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09771382	
Filing Date		2001-01-25	
First Named Inventor Ian Ri		chard Anselm Peak et al.	
Art Unit		1645	
Examiner Name Vanes		ssa L. Ford	
Attorney Docket Number		8795-24U1	

EXAMINER SIGNATURE								
Examiner Signature		Date Considered						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

1 See Kind Codes of USPTO Petert Documents at view (LSPTO_GOV) or MFPE 901.84. Enter of tice that issued the document, by the hot-letter code (WIPO_Standard S13.). "For Lapranese pater for the pater of beauting or the Emperor name precise the serial residency for begand of the compared the serial residency." A fixed of coursent by the appropriate symbols as indicated on the document under WIPO Standard S1.16 if possible. "Applicant is to place a check mark here if English language translation as attached."

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		09771382		
	Filing Date		2001-01-25		
	First Named Inventor Ian Ri		ichard Anselm Peak et al.		
	Art Unit		1645		
	Examiner Name Vanes		ssa L. Ford		
	Attorney Docket Number		8795-24U1		

CERTIFICATION STATEMENT

Please see	37	CFR 1	1.97	and	1.98 t	make the	appropriate	selection(s)
------------	----	-------	------	-----	--------	----------	-------------	------------	----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(e)(1)

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1,59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1,579(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature		Date (YYYY-MM-DD)	
Name/Print	Alan S. Nadel	Registration Number	27,363

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 Ond 37 CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, U.S. Operatment of Comments of Comment

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95-79) requires that you be given centain information in connection with your submission of the stacked form related to a penter application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is SU S. C. (2b)(2); (2) furnishing of the information solicided to is coluntary, and (3) the principal purpose for which the information is used by the U.S. Patent and Trademan XOTIEs is to process and/or examine your submission related to a patent agricultant or patent. If you do not furnish the requested process and/or examine your submission related to a patent agricultant or patent. If you do not furnish the requested requirement of the patent of the

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing coursel in the course of settlement negotiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the suited matter of the record
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S. C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals or part individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S. C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the accord was filed in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application peen to public inspections or an issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.